Labcorp Holdings Inc. (LH)

Labcorp's stock has experienced several notable events over the past six months. In Q1 2025, the company announced solid performance, exceeding analyst expectations and reaffirming its revenue and free cash flow guidance. In Q2 2025, Labcorp reported better-than-expected revenue and raised its full-year adjusted EPS guidance. In Q3 2025, the company reported adjusted earnings exceeding analyst estimates and updated its full-year EPS guidance. Labcorp announced a quarterly cash dividend of $0.72 per share, payable on December 11, 2025. Labcorp completed the acquisition of select oncology assets from BioReference Health for up to $225 million. The stock price has increased in the last 3 and 12 months.

While specific information regarding demand seasonality is not detailed, the clinical laboratory services market generally experiences relatively steady demand due to factors such as the prevalence of chronic and infectious diseases, an aging population, and the increasing adoption of preventive healthcare. Initiatives like annual wellness visits and subscription-style agreements can further flatten seasonal demand.

Labcorp Holdings, Inc. is a global life sciences company providing comprehensive laboratory services and end-to-end drug development services. Its core business revolves around Diagnostics Laboratories, offering a wide range of clinical lab tests, and Biopharma Laboratory Services, supporting pharmaceutical, biotechnology, and medical device companies. Labcorp is set to offer Roche's FDA-cleared Elecsys pTau181 blood test nationwide by early 2026.

Labcorp operates one of the largest clinical laboratory networks globally, with a presence in over 100 countries, primarily in the United States. Domestically, it manages approximately 2,000 patient service centers and over 30 U.S. reference and specialty labs. Internationally, Labcorp has more than 75 global labs dedicated to research, development, and clinical trial testing and operates manufacturing facilities in various countries.

Labcorp has maintained a positive brand reputation over the past year through strategic initiatives and advancements in its services. The company has formed new partnerships with health systems and regional laboratories and introduced innovative specialty tests. Labcorp has leveraged science and technology to improve customer experience and operational efficiency and demonstrated its commitment to ethical practices by issuing its 2024 Corporate Responsibility Report.

Institutional investors and hedge funds hold a significant majority of Labcorp's stock. Select Equity Group L.P., Nordea Investment Management AB, Invesco Ltd., Alliancebernstein L.P., and Lord Abbett & CO. LLC increased their holdings in the first and second quarters of 2025. Leeward Investments LLC MA trimmed its position in the second quarter, while D.A. Davidson & CO. increased its position during the same period.